IL33 and neoplasm: IPA revealed an important upregulation of (1) various signalling mediators, including eicosanoids, TREM1, and IL17; (2) several signalling pathways involved in the regulation of inflammation, immune response, and tumour progression including, oxytocin, ID1, activin inhibition, MSP-RON, IL33, and Th17-activation signalling pathways; and (3) MIF-mediated glucocorticoid and innate immunity regulation (Fig. 7a).